Literature DB >> 31283843

Etiology is the key determinant of neuroinflammation in epilepsy: Elevation of cerebrospinal fluid cytokines and chemokines in febrile infection-related epilepsy syndrome and febrile status epilepticus.

Kavitha Kothur1,2, Sushil Bandodkar3, Louise Wienholt4, Stephanie Chu4, Alun Pope5, Deepak Gill1,2, Russell C Dale1,2.   

Abstract

OBJECTIVE: To investigate intrathecal inflammation using cerebrospinal fluid (CSF) cytokines and chemokines in a subgroup of pediatric epilepsy patients with frequent daily seizures.
METHODS: We measured 32 cytokines/chemokines using multiplex immunoassay in CSF collected from pediatric patients with febrile infection-related epilepsy syndrome (FIRES)/FIRES-related disorders (FRD; n = 6), febrile status epilepticus (FSE; n = 8), afebrile status epilepticus (ASE; n = 8), and chronic epilepsy with frequent daily seizures (n = 21) and compared the results with noninflammatory neurological disorders (NIND; n = 20) and encephalitis (n = 43). We also performed longitudinal CSF cytokine/chemokine studies in three cases with FIRES/FRD.
RESULTS: The median age of onset of seizures was 2.4 years (range = 0.08-12.5). Median CSF timing from the onset of seizures was longer in chronic epilepsy (540 days), whereas FIRES, FSE, and ASE had CSF tested within 1-2 days of onset of seizures (P < .001). The elevation of cytokines/chemokines was higher in FIRES followed by FSE, when compared to chronic epilepsy and NIND controls. Th1-associated cytokines/chemokines (TNF-α, CXCL9, CXCL10, CXCL11), IL-6, CCL2, CCL19, and CXCL1 (P < .05) were elevated in FIRES, in contrast to the elevation of a broader network of cytokines/chemokines in encephalitis. The cytokines/chemokines (CXCL9, CXCL10, CXCL11, and CCL19) were elevated in FSE when compared to ASE despite the similar median seizure duration and timing of CSF testing in relation to seizures. Chronic epilepsy generally lacked significant elevation of cytokines/chemokines despite frequent daily seizures. The median concentrations of the cytokines/chemokines rapidly declined on serial testing during the course of illness in all three FIRES/FRD cases. SIGNIFICANCE: We identify significant differences in CSF cytokine/chemokine profile between FIRES/FRD and encephalitis. The prominent elevation of CSF cytokines and chemokines in FIRES/FRD and to a lesser extent FSE highlights that the cytokine/chemokine elevation is significantly associated with the etiology of the underlying process rather than purely reactive. However, it is unclear whether the immune activation contributes to the disease process. Wiley Periodicals, Inc.
© 2019 International League Against Epilepsy.

Entities:  

Keywords:  chemokine; cytokine; epilepsy; febrile infection-related epilepsy syndrome; febrile status epilepticus; inflammatory

Mesh:

Substances:

Year:  2019        PMID: 31283843     DOI: 10.1111/epi.16275

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  18 in total

Review 1.  Neuroinflammation and Proinflammatory Cytokines in Epileptogenesis.

Authors:  Alireza Soltani Khaboushan; Niloufar Yazdanpanah; Nima Rezaei
Journal:  Mol Neurobiol       Date:  2022-01-11       Impact factor: 5.590

2.  Emerging perspectives on mitochondrial dysfunctioning and inflammation in epileptogenesis.

Authors:  Shareen Singh; Thakur Gurjeet Singh
Journal:  Inflamm Res       Date:  2021-10-15       Impact factor: 4.575

3.  Systemic and cerebrospinal fluid immune and complement activation in Ugandan children and adolescents with long-standing nodding syndrome: A case-control study.

Authors:  Rodney Ogwang; Dennis Muhanguzi; Kioko Mwikali; Ronald Anguzu; Joe Kubofcik; Thomas B Nutman; Mark Taylor; Charles R Newton; Angela Vincent; Andrea L Conroy; Kevin Marsh; Richard Idro
Journal:  Epilepsia Open       Date:  2021-03-12

Review 4.  Unraveling the enigma of new-onset refractory status epilepticus: a systematic review of aetiologies.

Authors:  Simona Lattanzi; Markus Leitinger; Chiara Rocchi; Sergio Salvemini; Sara Matricardi; Francesco Brigo; Stefano Meletti; Eugen Trinka
Journal:  Eur J Neurol       Date:  2021-11-02       Impact factor: 6.288

5.  Liraglutide Is Protective against Brain Injury in Mice with Febrile Seizures by Inhibiting Inflammatory Factors.

Authors:  Xing Wang; Fei Yang; Liling Deng; Di Qiu; Yao Liu; Yang Kang
Journal:  Comput Math Methods Med       Date:  2022-04-29       Impact factor: 2.809

6.  Sevoflurane as bridge therapy for plasma exchange and Anakinra in febrile infection-related epilepsy syndrome.

Authors:  Manuela L'Erario; Rosa Maria Roperto; Anna Rosati
Journal:  Epilepsia Open       Date:  2021-10-20

Review 7.  Advances regarding Neuroinflammation Biomarkers with Noninvasive Techniques in Epilepsy.

Authors:  Hongrui Ma; Hua Lin
Journal:  Behav Neurol       Date:  2021-12-22       Impact factor: 3.342

Review 8.  Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy.

Authors:  Gaku Yamanaka; Yu Ishida; Kanako Kanou; Shinji Suzuki; Yusuke Watanabe; Tomoko Takamatsu; Shinichiro Morichi; Soken Go; Shingo Oana; Takashi Yamazaki; Hisashi Kawashima
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

9.  Epilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects.

Authors:  Stephen F Traynelis; Dennis Dlugos; David Henshall; Heather C Mefford; Michael A Rogawski; Kevin J Staley; Penny A Dacks; Vicky Whittemore; Annapurna Poduri
Journal:  Epilepsy Curr       Date:  2020-01-22       Impact factor: 7.500

Review 10.  Neurocritical care and target immunotherapy for febrile infection-related epilepsy syndrome.

Authors:  Hiroshi Sakuma; Asako Horino; Ichiro Kuki
Journal:  Biomed J       Date:  2020-04-21       Impact factor: 4.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.